EMEA-000056-PIP03-10-M02
Key facts
| Invented name |
Avastin
|
| Active substance |
bevacizumab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0005/2014
|
| PIP number |
EMEA-000056-PIP03-10-M02
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of high-grade glioma
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Roche Registration Ltd
|
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-000056-PIP03-10-M02
|
| Compliance opinion date |
13/11/2015
|
| Compliance outcome |
positive
|